Sona Nanotech to Arrange Private Placement Financing
Halifax, Nova Scotia--(Newsfile Corp. - July 31, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that it plans to raise up to $1,500,000 through a private placement financing (the "Financing") of up to 6,000,000 common shares of Sona (each, a "Share") at a price of $0.25 per Share (the "Offering Price"). Insiders and certain other existing shareholders of Sona may also subscribe for Shares under the Financing. Numus Capital Corp. (the...
2024-07-31 8:22 AM EDT
Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study
Halifax, Nova Scotia--(Newsfile Corp. - June 26, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that a detailed biomarker analysis of the recently reported pre-clinical melanoma study conducted at Dalhousie University (the "Study") indicates that, beyond shrinking tumors on its own, Sona's Targeted Hyperthermia Therapy ("THT") also stimulates the innate immune system to target and eliminate untreated (contralateral) tumors when combined...
2024-06-26 9:54 AM EDT
Sona's Therapy Shows Significant Preclinical Efficacy in Second Cancer
Halifax, Nova Scotia--(Newsfile Corp. - June 20, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that its targeted hyperthermia therapy ("THT") demonstrated positive results in a second preclinical cancer model. Findings just presented at the 2024 STING & TLR Targeted Therapies Summit for immunotherapies in San Diego, California, show that Sona's THT achieved responses in a preclinical melanoma model equal to that which was recently...
2024-06-20 9:45 AM EDT
Sona Appoints Chief Medical Officer and Files Provisional Conjugation Patent
Halifax, Nova Scotia--(Newsfile Corp. - May 21, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to advise that it has appointed Dr. Carman Giacomantonio MD, MSc., FRCSC (Cav.) to be the Company's Chief Medical Officer. Dr. Giacomantonio is a practicing Surgical Oncologist at the QEII Health Sciences Centre and a Professor of Surgery at Dalhousie University. Dr. Giacomantonio leads a productive translational research group at Dalhousie University and...
2024-05-21 9:09 AM EDT
Sona's Cancer Therapy Creates a Systemic Immune Response in Murine Breast Cancer Model
Halifax, Nova Scotia--(Newsfile Corp. - April 29, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces further results from the triple negative breast cancer murine model portion of its current research study at Dalhousie University (the "Study") which confirms that the previously reported tumor volume reduction was due to activation of a tumor specific systemic immune response. These data relate to the follow-up biomarker analysis performed on the...
2024-04-29 9:32 AM EDT
Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study
Halifax, Nova Scotia--(Newsfile Corp. - April 12, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce further positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). The Company was provided with data from the Study that indicates the response in a pre-clinical triple negative breast cancer model treated with the combination of Sona's targeted hyperthermia therapy...
2024-04-12 8:35 AM EDT
Sona Nanotech Secures Grant Funding to Support Intellectual Property Strategy and Development
Halifax, Nova Scotia--(Newsfile Corp. - April 8, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces that it has been approved for funding totaling approximately $40,000 to support the development of its intellectual property portfolio. The Company is receiving advisory services and up to $24,894 in funding from the National Research Council of Canada Industrial Research Assistance Program ("NRC IRAP") IP Assist program to support the development of an...
2024-04-08 8:47 AM EDT
Sona Nanotech Updates on Dalhousie Efficacy Study and New NCL Results
Halifax, Nova Scotia--(Newsfile Corp. - March 25, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). An update received by the Company indicates that all tumors treated within the Study to date with a single Targeted Hyperthermia Therapy ("THT") treatment shrunk within the first 24 hours, with an average reduction in size...
2024-03-25 9:27 AM EDT
Sona Nanotech Announces Filing of Provisional Patent Application
Halifax, Nova Scotia--(Newsfile Corp. - March 18, 2024) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that it has submitted a provisional patent application with the United States Patent and Trademark Office (USPTO), for its proprietary photothermal light device, entitled, "ENDOSCOPE WITH EMR OPTICAL FIBER AND THERMAL SENSOR FOR PHOTOTHERMAL THERAPY".A prototype of Sona's medical laser was engineered in conjunction with Minnetronix Medical to apply...
2024-03-18 9:21 AM EDT
Sona Nanotech Grants Options
Halifax, Nova Scotia--(Newsfile Corp. - March 1, 2024) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that that it has granted 1,195,000 incentive stock options under the Company's Stock Option Plan ("Option Plan"), of which 810,000 have been granted to a Directors and Officers. Each option is exercisable into one common share at a price of $0.31 per share and will vest at the rate of 25% every six months. The options will expire five...
2024-03-01 9:03 AM EST
Sona Nanotech Announces Director Retirement
Halifax, Nova Scotia--(Newsfile Corp. - January 10, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces that Dr. Michael Gross has retired from the Company's Board of Directors (the "Board") to focus on other business interests. "Mike has been a valuable member of Sona's Board, and we wish him great success in his future endeavours," stated Mark Lievonen, Chair of Sona. Dr. Gross commented, "I am proud of the recent accomplishments the Company has...
2024-01-10 8:55 AM EST
Sona Nanotech Closes Private Placement Financing to Raise $750,000 in Gross Proceeds and Announces Additional Financing
Halifax, Nova Scotia--(Newsfile Corp. - November 27, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has closed its private placement that was announced on October 18, 2023 with the issuance of 3,750,000 shares at $0.20 per share and 1,875,000 common share purchase warrants exercisable to purchase an additional common share of Sona at a price of $0.30 per share until November 24, 2025. (the "Financing"). Insiders subscribed...
2023-11-27 8:59 AM EST
Sona Nanotech Arranges Brokered Private Placement Financing
Halifax, Nova Scotia--(Newsfile Corp. - October 18, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that it plans to raise up to $750,000 through a brokered private placement (the "Financing") of up to 3,750,000 units of Sona (each, a "Unit") at $0.20 per Unit (the "Offering Price"). Each Unit will consist of one common share of Sona (a "Common Share") and one-half (1/2) of a common share purchase warrant (each whole...
2023-10-18 8:36 AM EDT
Sona Provides Corporate Update on Operating Activities
Halifax, Nova Scotia--(Newsfile Corp. - October 12, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona"), a nanotechnology life sciences company with proprietary manufacturing technology for biocompatible gold nanorods ("GNRs"), is pleased to provide an update on the status of its current operating activities, notably the development of its Targeted Hyperthermia Therapy ("THT") therapy and its rapid bovine tuberculosis prototype test. Sona CEO, David Regan,...
2023-10-12 1:21 PM EDT
Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study
Halifax, Nova Scotia--(Newsfile Corp. - September 11, 2023) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce an innovative research initiative to be undertaken with The Giacomantonio Immuno-Oncology Research Group (the "Research Group"). This study aims to evaluate the efficacy of Sona's Targeted Hyperthermia Therapy ("THT") technology in not only attenuating the development of colorectal, breast, and melanoma tumor models in mice but also in...
2023-09-11 8:50 AM EDT
Sona to Engage with Medical Experts and Payors to Inform Regulatory and Commercialization Strategies for Its 'THT' Cancer Therapy
Halifax, Nova Scotia--(Newsfile Corp. - September 5, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce it has partnered with EXCITE International ("EXCITE"), a global network of senior specialist physicians, payors, health systems, and end-users, to help guide the development of Sona's Targeted Hyperthermia Therapy. Through this partnership with EXCITE, Sona will gain access to EXCITE's global network to help it align pre-clinical and...
2023-09-05 9:31 AM EDT
Sona Nanotech Grants Options
Halifax, Nova Scotia--(Newsfile Corp. - July 11, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF), (the "Company") is pleased to announce that it has granted 900,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") of which 825,000 have been granted to a Directors and Officers. Each option is exercisable into one common share at a price of $0.25 per share. 600,000 options will vest at the rate of 25% every six months and 300,000 options...
2023-07-11 8:50 AM EDT
New NCL Assessment of Sona's GNR Technology Highlights Process Improvement Success
Halifax, Nova Scotia--(Newsfile Corp. - June 8, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has received the third set of results of an independent assessment of its proprietary gold nanorod nanoparticles from the U.S. National Cancer Institute's Nanotechnology Characterization Laboratory ("NCL"). In addition to running similar assessments to those that have been previously announced for contamination and endotoxin levels,...
2023-06-08 9:39 AM EDT
Sona Nanotech Selects Minnetronix to Engineer Its Next Generation Targeted Hyperthermia Cancer Therapy Light Device
Halifax, Nova Scotia--(Newsfile Corp. - May 30, 2023) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona"), a nanotechnology company developing pre-clinical Targeted Hyperthermia Therapy ("THT") for colorectal cancer, is pleased to announce the selection of Minnetronix Medical to engineer the next generation of its infrared light device. The device will be used in Sona's development of THT to transfer energy by way of infrared light to Sona's proprietary, biocompatible...
2023-05-30 8:19 AM EDT
Sona Nanotech Elects New Board Chair and is Awarded Patent
Halifax, Nova Scotia--(Newsfile Corp. - May 18, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona"), a nanotechnology company developing pre-clinical Targeted Hyperthermia Therapy for colorectal cancer, is pleased to announce the election as chair of the board, Mr. Mark Lievonen, CM, who joined the board of Sona in December 2020. Mr. Lievonen served as president of Sanofi Pasteur Limited from 1999 to 2016, during which time it became a billion-dollar enterprise in...
2023-05-18 8:41 AM EDT